Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7885580 | 1.00 | CASP3 (0.43) | CASP3PTPN1MDM2 | |
| SCHEMBL29608924 | 0.90 | PTPN1 (0.46) | CASP3PTPN1MDM2 | |
| SCHEMBL30205216 | 0.88 | PTPN1 (0.47) | CASP3PTPN1MDM2 | |
| SCHEMBL7971614 | 0.88 | PTPN1 (0.47) | CASP3PTPN1MDM2 | |
| SCHEMBL31720035 | 0.88 | PTPN1 (0.47) | CASP3PTPN1MDM2 | |
| SCHEMBL30828461 | 0.87 | PTPN1 (0.50) | CASP3PTPN1MDM2 | |
| SCHEMBL31144246 | 0.85 | MDM2 (0.46) | CASP3MDM2 | |
| SCHEMBL31094981 | 0.84 | PTPN1 (0.48) | CASP3PTPN1MDM2 | |
| SCHEMBL20998310 | 0.84 | PTPN1 (0.49) | PTPN1MDM2 | |
| SCHEMBL5065049 | 0.83 | MDM2 (0.45) | CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291553-B2 | Non-opioid anti-pain medication | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-06 | — | — | US | disclosed |
| EP-3914280-B1 | NOVEL NON-OPIOID ANTI-PAIN MEDICATION | UNIV TEXAS (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220185855-A1 | NOVEL NON-OPIOID ANTI-PAIN MEDICATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291553-B2 | Non-opioid anti-pain medication | FGF1, FGF2, FGF23 | CASP3 2574/4885PTPN1 158/4885MDM2 4505/4885 |
| US-20220185855-A1 | NOVEL NON-OPIOID ANTI-PAIN MEDICATION | FGF1, OGFR, OPRL1 | CASP3 2601/4885PTPN1 315/4885MDM2 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.